Myriad Genetics Announces The Incorporation Of Its HRD Platform In Illumina's Updated Gene Panel Assay
Myriad Genetics Announces Incorporation of Its Proprietary HRD Platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 V2
Myriad Genetics Announces Prequel Prenatal Screening Can Now Be Performed Eight Weeks Into Pregnancy
Morgan Stanley Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $21
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
MYGN Stock Might Gain From SneakPeek Availability in Retail Stores